Salarius Pharmaceuticals Inc (SLRX)

NASDAQ
2.5600
+0.0900(+3.64%)
After Hours
2.5700
+0.0100(+0.3906%)
- Real-time Data
  • Volume:
    215,546
  • Day's Range:
    2.5100 - 2.8499
  • 52 wk Range:
    1.0700 - 13.4575

SLRX Overview

Prev. Close
2.47
Day's Range
2.51-2.8499
Revenue
-
Open
2.6
52 wk Range
1.07-13.4575
EPS
-14.57
Volume
215,546
Market Cap
5.83M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
167,996
P/E Ratio
-0.18
Beta
0.798
1-Year Change
-76.71%
Shares Outstanding
2,278,227
Next Earnings Date
Mar 27, 2023
What is your sentiment on Salarius Pharmaceuticals?
or
Market is currently closed. Voting is open during market hours.

Salarius Pharmaceuticals Inc News

Salarius Pharmaceuticals Inc Analysis

Salarius Pharmaceuticals Inc Company Profile

Salarius Pharmaceuticals Inc Company Profile

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical need. In addition, the Company is also developing treatments for cancers caused by dysregulated gene expression. The Company is developing two classes of drugs that address gene dysregulation: epigenetic drugs and targeted protein degraders. The Company’s technologies have the potential to work in both liquid and solid tumors. The Company’s pipeline consists of two compounds: seclidemstat (SP-2577), which is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1); SP-2577 uses a reversible mechanism to inhibit LSD1’s enzymatic and scaffolding properties and thereby treat and prevent cancer progression, and SP-3164, which is a cereblon binding molecular glue and has a development path in hematological cancer and potential in solid tumors.

Read More

Analyst Price Target

Average70.5000 (+2,653.9063% Upside)
High125.0000
Low16.0000
Price2.5600
No. of Analysts2
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellSellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellBuyStrong Sell
SummaryStrong SellStrong SellStrong SellNeutralStrong Sell
  • from half a dollar to 5 in the coming year. Just before publishing groundbreaking data
    0
    • the stock falls but before December 21 will hopefully think that it raises to $15
      0
      • someday some good news is going come out, and this stock it's going to shoot up hundreds of percents
        1
        • yes
          0
      • is this a scam stock
        2
        • there are many big guys on it, i can't say for sure but i seems improbable to me
          0
      • hmmm..if it drops to sub $2 before close maybe tomorrow could bring $3 with some post and premarket push
        1
        • My interpretation of the digital meeting held today with investors is that this is a very potential trigger for increase.
          0
      • http://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-present-diamond-equity-research Sounds to me like this Stock problary will increase futher after today? After this meeting with investors
        0
        • Moving to phase 2 of testing today with seclidemstat & will look to announce recent findings soon. Good signs.
          0
          • The stock is tanking today how come ?
            0
            • toidi people selling
              0
          • Buying more :)
            0
            • Expecting an increase past $4
              0